The strategic collaboration aims to improve the conditions for developing and implementing personalised medicine in healthcare through joint efforts in research, technology development and patient collaboration.

The collaboration is based on a shared vision to create competitive ecosystems for genomics and precision medicine.

The collaboration is based on a shared vision to create competitive ecosystems for genomics and precision medicine. By combining expertise and resources, the countries can accelerate the development of precision diagnostics and personalized medicine, improving healthcare and benefiting patients in both countries.

The original MoU was written in 2022, and the updated MoU was signed by Richard Rosenquist Brandell, Director of GMS and Bettina Lundgren, Director of DNGC, on December 17, 2024 during a joint workshop in Copenhagen.

“We look forward to continuing to share experiences on the implementation of precision diagnostics in healthcare, data sharing and health economics, as well as other important areas,” says Richard Rosenquist Brandell about the continued collaboration.

The collaboration focuses on exchange of experience in bioinformatics analysis, secure storage and access to genomics data, legal and ethical issues related to the use of data, development of health economic models, strengthened participation in EU projects to position Sweden and Denmark as leaders in personalized medicine, and models for patient engagement and education of health professionals and the public.

To promote the development of genomics and precision medicine, GMS has a broad international engagement. In September, a renewed MoU was signed with the French Genomic Medicine initiative and GMS also has an existing MoU with the Centers for Personalized Medicine, ZPM, in Germany to promote the development of precision medicine.